Five More Deaths, FDA Alerts on Liquid-Filled Intragastric Balloons
Five more deaths have been reported in patients where liquid-filled intragastric balloon systems were used to treat obesity. That brings the total number of deaths to 12 patients worldwide since 2012.
MedTech Intelligence last reported on this issue in August 2017, with the cases involving the Orbera Intragastric Balloon System and the ReShape Integrated Dual Balloon System.
Last week the FDA approved labeling changes that indicated deaths could be associated with the above-mentioned devices. The agency is also monitoring complications associated with device placement and use, which includes perforation of the stomach wall or esophagus, acute pancreatitis, and spontaneous hyperinflation. Healthcare providers have also been advised to monitor patients who have these balloons for complications.
Related Articles
-
The agency has alerted healthcare providers of unanticipated deaths related to the systems intended to treat obesity.
-
Device manufacturers and importers will have two years to modify their Quality Systems to meet the requirements of the QMSR rule by February 2, 2026.
-
Jordi labs and its team of Ph.D. analytical chemists developed a proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements.
-
On May 16-17, device developers, regulatory affairs and regulatory intelligence professionals will come together in Washington, DC, for two days of education, discussion and networking to share strategies and best practices on navigating current and on the horizon regulatory requirements.
